Krishnan Ramanathan, Ph.D., appointed chief executive officer of Gates Medical Research Institute
CAMBRIDGE, Massachusetts (November 16, 2026)—The Gates Medical Research Institute (Gates MRI) Board of Directors announced today the appointment of Krishnan (Krish) Ramanathan, as chief executive officer (CEO). Krish has served as interim CEO since April 2026 and previously served as Gates MRI’s chief of staff and head of development.
“Scientific breakthroughs have the potential to significantly improve health around the world but only if they reach the people who stand to benefit from them,” said Trevor Mundel, president of Global Health at the Gates Foundation and chair of the Gates MRI Board of Directors. “Krish understands what it takes to move promising discoveries from the lab to the people whose lives they could change. His deep experience in drug and vaccine development, combined with his commitment to partnership, will be invaluable as Gates MRI works to accelerate progress against diseases like tuberculosis and help build a future where no one is denied the chance to live a healthy life because of where they were born.”
Krish brings 26 years of experience in the pharmaceutical and biotechnology industries, including leadership of development programs across vaccines and treatments. Building partnerships that support research, development, and the delivery of new medical innovations has been central to his work.
Gates MRI is a non-profit affiliate of the Gates Foundation advancing the development of medical interventions addressing substantial health concerns of lower- and middle-income countries (LMICs), through a network of collaborating partners and organizations. Gates MRI is currently sponsoring a Phase III clinical trial to assess a vaccine candidate designed to protect adolescents and adults from tuberculosis (TB). The institute is also advancing several experimental compounds for possible inclusion in new TB treatment regimens.
“Gates MRI is focused on accelerating the development of lifesaving medical innovations for the people who need them most,” said Krish. “As we pursue promising new vaccines and treatments, we will continue to support the partnerships and systems needed to make these innovations accessible, once they are approved by regulatory authorities, to the people who could benefit from them.”
Prior to joining the Gates MRI in 2025, Krish served as senior vice president and head of immunology portfolio & assets at Johnson & Johnson Innovative Medicines R&D, where he led teams overseeing early- and late-stage development. Before joining Johnson & Johnson, he spent 15 years at Novartis, where he held leadership roles spanning multiple therapeutic areas, leading teams to successful regulatory approvals. Krish holds a Ph.D. and an M.S.E. in biomedical engineering from Johns Hopkins University and an undergraduate degree in mechanical engineering from the Indian Institute of Technology.
About the Gates Medical Research Institute (Gates MRI)
The Gates Medical Research Institute is a nonprofit medical research organization dedicated to the development and effective use of novel biomedical interventions addressing substantial global health concerns where incentives for investment are limited. For more information, visit www.gatesmri.org.
Media contact: media@gatesmri.org